Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.79 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.79 |
| ▸ | PIK3CB | P42338 | 10/20 | 0.79 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.79 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.79 |
| ▸ | PIK3R1 | P27986 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13075389 | 1.00 | PIK3CD (0.79) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL13076084 | 0.91 | PIK3CD (0.66) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL13075178 | 0.89 | PIK3CA (0.73) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL660510 | 0.88 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL173490 | 0.88 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL19221914 | 0.88 | PIK3CD (0.77) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL29394358 | 0.88 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL657898 | 0.88 | PIK3CD (1.00) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL13075809 | 0.86 | PIK3CD (0.64) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL16266146 | 0.84 | PIK3CD (0.74) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280029-A1 | NOVEL COMPOUNDS | PIK3CD, PIK3CA, PIK3C2B | PIK3CD 1/4885PIK3CA 2/4885PIK3CB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.